| Peer-Reviewed

Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon

Received: 22 July 2022     Accepted: 12 August 2022     Published: 24 August 2022
Views:       Downloads:
Abstract

Malaria and HIV share common determinants of vulnerability and, HIV/HCV coinfection accelerates the progression to AIDS causing millions of deaths each year worldwide. The aim of the study was to determine epidemiological and immunological profile of HIV in HCV and Plasmodium coinfection context. All adults (≥ 17 years) volunteers for HIV testing and attending the Voluntary Testing Center of Douala Laquintinie Hospital were consecutively recruited over a period of seven months. Anonymous questionnaire was used to explore demographics, circumstances and reasons for testing, knowledge, attitudes, and behaviors. HIV diagnosis were performed using Rapid Diagnostic Test (RDT) and ELISA, whereas RDT were used for HCV and Plasmodium falciparum infection diagnosis. Quantification of HIV-1 specific CD4 and transaminases were based on FACS Count and spectrophotometer respectively. Overall, 25.6%, 6.4% and 24.8% of 125 adults had HIV, HCV and Plasmodium infection respectively. HIV/Plasmodium, HCV/Plasmodium and HIV/HCV coinfection was reported in 9, 2 and 1 consultant(s) respectively. Based on the WHO classification, severe immunosuppression (CD4 count < 200 cells/mm3) was recorded in HIV and Plasmodium monoinfected individuals: 12.5% and 6.6% respectively. For HIV mono-infected consultants, 12.5% were highly immunocompromised and 43.75% had a CD4 count between 500 and 2000 cells/mm3. Severe immunosuppression was more marked in HIV/Plasmodium (22.2%). HIV and Plasmodium mono-infected patients had higher hyperparasitemia compared to non-infected and the same result was observed with HCV/Plasmodium co-infected patients (42.8%) and HCV/Plasmodium co-infected patients. Severe immunosuppression was recorded in both HIV and Plasmodium monoinfected individuals. This severe immunosuppression was more pronounced in HIV/Plasmodium and HIV/HCV/Plasmodium coinfected patients. HIV and Plasmodium mono-infected patients had more pronounced hypertransaminasemia in women than in men.

Published in Advances in Applied Sciences (Volume 7, Issue 3)
DOI 10.11648/j.aas.20220703.18
Page(s) 84-92
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

HIV, HCV, Plasmodium, Coinfection, CD4, Transaminases, Voluntary Counseling and Testing, Cameroun

References
[1] Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV infected Individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. 2008; 22: 1979-1991.
[2] Graham C, Baden L, Yu E. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33: 562-569.
[3] Zylberberg H., Pol, S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin. Infect. Dis. 1996; 1117-25. Review.
[4] Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill. 2008; 13 (22): pii=18888. Available at http://wwweurosurveillance.org/ViewArticle?aspx?ArticleId=18888.
[5] Eze AD, Ibeziako NS, Ikefuna AN, Nwokoye IC, Uleanya ND, Ilechukwu GC. Prevalence and risk for hepatitis C and factoring human immunodeficiency virus co-infection among children in Enugu, Nigeria. Afr. J. Infect. Dis. 2014; 5-8.
[6] King S, Adjei-Asante K, Appiah L, Adinku L, Beloukas A, Atkins M. et al. Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection Among HIV-infected adults in Ghana. J. Viral Hepat. 2015; 22 (5): 461-8.
[7] Musyoki AM, Msibi TL, Motswaledi MH, Selabe SG, Monokoane TS, Mphahlele MJ. Active co-infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy. J. Med. Virol. 2015; 87 (2): 213-21.
[8] Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIVpositive and HIV-negative pregnant women in Abidjan, Côte d’Ivoire: the ANRS 1236 study. J Med Virol. 2004; 74 (1): 34-40.
[9] Slutsker L, Marston BJ. HIV and malaria: interactions and implications. Curr Opin Infect Dis. 2007; 20 (1): 3-10.
[10] Laufer K, Plowe CV. The interaction between HIV and Malaria in Africa. Curr. Infect Dis Rep. 2007; 9 (1): 47-54.
[11] WHO (World Health Organization). Malaria-infected patients with HIV/AIDS. 2013. 23p. Available at: http://www.who.int/malaria/areas/high_risk_groups/hiv_aids_patients/fr/. Accessed December 2020.
[12] WHO (World Health Organization). Inter-share data between malaria and HIV and the impact of these interactions on prevention efforts and the fight against both diseases. 2004; 21p. Available at: http://www.who.int/hiv/pub/meetingreports/malariahivfr.pdf. Accessed March 2021.
[13] Kfutwah A, Mary JY, Lemen B, Leke R, Rousset D, Barre-Sinoussi F et al. Plasmodium falciparum infection odd significantly placental cytokine profile in HIV infected Cameroonian women. PLoS One. 2009; 4 (12): e8114.
[14] Matthews GV, Manzini P, Hu Z, P Khabo, Maja P, Matchaba G, et al. Impact of HIV and lamivudine were hepatitis B virus-related outcomes in HIV / hepatitis B virus Individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. 2011; 25: 1727-1735.
[15] Lawrence C, Bourgeois A, Mpoudi Ngole-E, Kouanfack C, Ciaffi L, Nkoue N, et al. High rates of active hepatitis B and C HIV-1 co-infection in infected adults initiating event Cameroonian antiretroviral therapy. HIV Med. 2010; 11: 85-9.
[16] Hoffmann CJ, Charalambous S, Martin Innes DJ, Churchyard C, Chaisson RE. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008; 47: 1479-1485.
[17] Ashir GM, Rabasa AI, Gofama MM, Bukbuk D, Abubakar H, Farouk GA. Study of hepatic functions and prevalence of hepatitis B surface area antigenaemia in Nigerian children with human immunodeficiency virus infection. J. Med. 2009; 18: 260-2.
[18] Biwole-Sida M, Noah Noah D, Eloumou AF, Dang I, Talla P, Malongue C et al. Carriage prevalence of HCV markers in the working environment (Cameroon). Afr J of hepatol-ent. 2015; 9: 26-29.
[19] WHO (World Health Orgnisation). World Malaria Report 2021. Briefing kit-Global messaging. 2022; 24p. Available at https://cdn.who.int›docs›world-malaria-reports. Accessed Juin 2022.
[20] Biadglegne F, Belyhun Y, Tessema B. Sero-prevalence of human immunodeficiency virus (HIV) voluntary counseling and testing Among (VCT) customers in Burie Health Center, West Gojjam, Ethiopia. Ethiop Med J. 2010; 48 (2): 149-56.
[21] National Institute of Statistics, Ministry of Economics Planning and Regional Development, Ministry of Public Health. Republic of Cameroon: Demographic and Health Survey and Multiple Indicator (DHS-IMI) 2011. Preliminary Report on HIV prevalence. ICF International Calverton, Maryland, Cameroon. 2012; 576p. French file. Available at https://www.dhsprogram.com›pubs›pdf. Accessed February 2022.
[22] Dikosso E. Seroprevalence of HIV and hepatitis B among blood donors in Laquintinie hospital in Douala. Medical Thesis Degree. Faculty of Medicine and Biological Sciences, University of Yaounde I. 2010; 98 p. French file. Available at https://www.researchgate.net › 2601. Accessed February 2022.
[23] Eboumbou Moukoko EC, Ngo Sack, Essangui Same EG, Mbangue Madeleine, Lehman LG. HIV, HBV, HCV infections and T. pallidum among blood donors and transfusion related complications in Laquintinie containers at the hospital in Douala, Cameroon. BMC Hematology. 2014; 14: 5-9.
[24] WHO (World Health Orgnisation) and UNAIDS. Update on the AIDS epidemic. 2006; 96p. Availle at http://data.unaids.org › 2006 › 2006_epiupdate_en. Accessed June 2022.
[25] Delaporte E, Dazza M, Larouzé C. Epidemiology of HCV. Med Mal Infect. 1995; 25: 1084-8.
[26] Denis F, Aussel L, Ranger S, Martin P, Itoua N'Gaporo-A, Frommel D et al. Prevalence of antibodies to hepatitis C virus Among with leprosy patients in several African countries and the Yemen. J. Med. Virol. 1995; 43: 1-4.
[27] Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002; 2: 293-302.
[28] Newman J, Perez Iriondo J, Foday Hemingway J, Freeman A, Akam W, Balimba A et al. Older Adults Accessing HIV Care and Treatment and Adherence in the DEA, Central Africa Cohort. AIDS Res Treat. 2012; 725713.
[29] Koanga Mogtomo ML, Louandji Fomekong S, Fotso Kuate H, Ngono Ngane A. Detection of infectious agents in blood banks Douala (1995-2004). Notebook studies and Francophone / Health Research. 2009; 19: 3-8.
[30] Lehman GL. Fight against malaria in Douala, Cameroon. Regional validation workshop of the roadmap for the fight against malaria and the action plan in the private sector in Francophone Africa COTONOU 3-4 June 2014. Available at https://www.santeentreprise.com/spot-paluthon-15-au-25-avril-2015/. Accessed February 2022.
[31] Mbanya DN, Takam D, Ndumbe PM. Serological Findings Amongst first-time blood donors in Yaounde, Cameroon: donation is safe to myth or reality? Transfus Med. 2003; 13: 267-273.
[32] Kabore R. Followed by the evolution of biological parameters in HIV-positive patients treated at the research center Pietro Annigoni biomolecular (CERBA) and Saint Camille medical center (CMSC) of Ouagadougou. Master 2 Degree; Faculty of Sciences, University of Ouagadougou. 2010; 102 p. French file. Available at https://www.researchgate.net/scientific-contributions. Accessed February 2022.
[33] Gopal DV, Rossen HR. Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med. 2000; 107 (2): 100-2, 105-9, 113-4.
[34] Poynard T, Marcellin P, Lee SS, Niederau C, Unmik GS, Ideo G. et al. Randomised trial of interferon plus ribavirin alpha2b for 48 weeks or for 24 weeks versus interferon plus placebo alpha2b for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). 1998; 352 (9138): 1426-1432.
[35] Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000; 342: 1266-1271.
Cite This Article
  • APA Style

    Serge Bruno Ebong, Calixte Ida Penda, Essangui Same Estelle, Juste Patient Mbebi Enone, Madeleine Mbangue, et al. (2022). Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon. Advances in Applied Sciences, 7(3), 84-92. https://doi.org/10.11648/j.aas.20220703.18

    Copy | Download

    ACS Style

    Serge Bruno Ebong; Calixte Ida Penda; Essangui Same Estelle; Juste Patient Mbebi Enone; Madeleine Mbangue, et al. Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon. Adv. Appl. Sci. 2022, 7(3), 84-92. doi: 10.11648/j.aas.20220703.18

    Copy | Download

    AMA Style

    Serge Bruno Ebong, Calixte Ida Penda, Essangui Same Estelle, Juste Patient Mbebi Enone, Madeleine Mbangue, et al. Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon. Adv Appl Sci. 2022;7(3):84-92. doi: 10.11648/j.aas.20220703.18

    Copy | Download

  • @article{10.11648/j.aas.20220703.18,
      author = {Serge Bruno Ebong and Calixte Ida Penda and Essangui Same Estelle and Juste Patient Mbebi Enone and Madeleine Mbangue and Samuel Honore Mandengue and Carole Else Eboumbou Moukoko},
      title = {Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon},
      journal = {Advances in Applied Sciences},
      volume = {7},
      number = {3},
      pages = {84-92},
      doi = {10.11648/j.aas.20220703.18},
      url = {https://doi.org/10.11648/j.aas.20220703.18},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.aas.20220703.18},
      abstract = {Malaria and HIV share common determinants of vulnerability and, HIV/HCV coinfection accelerates the progression to AIDS causing millions of deaths each year worldwide. The aim of the study was to determine epidemiological and immunological profile of HIV in HCV and Plasmodium coinfection context. All adults (≥ 17 years) volunteers for HIV testing and attending the Voluntary Testing Center of Douala Laquintinie Hospital were consecutively recruited over a period of seven months. Anonymous questionnaire was used to explore demographics, circumstances and reasons for testing, knowledge, attitudes, and behaviors. HIV diagnosis were performed using Rapid Diagnostic Test (RDT) and ELISA, whereas RDT were used for HCV and Plasmodium falciparum infection diagnosis. Quantification of HIV-1 specific CD4 and transaminases were based on FACS Count and spectrophotometer respectively. Overall, 25.6%, 6.4% and 24.8% of 125 adults had HIV, HCV and Plasmodium infection respectively. HIV/Plasmodium, HCV/Plasmodium and HIV/HCV coinfection was reported in 9, 2 and 1 consultant(s) respectively. Based on the WHO classification, severe immunosuppression (CD4 count 3) was recorded in HIV and Plasmodium monoinfected individuals: 12.5% and 6.6% respectively. For HIV mono-infected consultants, 12.5% were highly immunocompromised and 43.75% had a CD4 count between 500 and 2000 cells/mm3. Severe immunosuppression was more marked in HIV/Plasmodium (22.2%). HIV and Plasmodium mono-infected patients had higher hyperparasitemia compared to non-infected and the same result was observed with HCV/Plasmodium co-infected patients (42.8%) and HCV/Plasmodium co-infected patients. Severe immunosuppression was recorded in both HIV and Plasmodium monoinfected individuals. This severe immunosuppression was more pronounced in HIV/Plasmodium and HIV/HCV/Plasmodium coinfected patients. HIV and Plasmodium mono-infected patients had more pronounced hypertransaminasemia in women than in men.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Biological and Immunological Profile of HIV Voluntary Consultants with HCV and Plasmodium Coinfection in One Accredited Treatment Center in Cameroon
    AU  - Serge Bruno Ebong
    AU  - Calixte Ida Penda
    AU  - Essangui Same Estelle
    AU  - Juste Patient Mbebi Enone
    AU  - Madeleine Mbangue
    AU  - Samuel Honore Mandengue
    AU  - Carole Else Eboumbou Moukoko
    Y1  - 2022/08/24
    PY  - 2022
    N1  - https://doi.org/10.11648/j.aas.20220703.18
    DO  - 10.11648/j.aas.20220703.18
    T2  - Advances in Applied Sciences
    JF  - Advances in Applied Sciences
    JO  - Advances in Applied Sciences
    SP  - 84
    EP  - 92
    PB  - Science Publishing Group
    SN  - 2575-1514
    UR  - https://doi.org/10.11648/j.aas.20220703.18
    AB  - Malaria and HIV share common determinants of vulnerability and, HIV/HCV coinfection accelerates the progression to AIDS causing millions of deaths each year worldwide. The aim of the study was to determine epidemiological and immunological profile of HIV in HCV and Plasmodium coinfection context. All adults (≥ 17 years) volunteers for HIV testing and attending the Voluntary Testing Center of Douala Laquintinie Hospital were consecutively recruited over a period of seven months. Anonymous questionnaire was used to explore demographics, circumstances and reasons for testing, knowledge, attitudes, and behaviors. HIV diagnosis were performed using Rapid Diagnostic Test (RDT) and ELISA, whereas RDT were used for HCV and Plasmodium falciparum infection diagnosis. Quantification of HIV-1 specific CD4 and transaminases were based on FACS Count and spectrophotometer respectively. Overall, 25.6%, 6.4% and 24.8% of 125 adults had HIV, HCV and Plasmodium infection respectively. HIV/Plasmodium, HCV/Plasmodium and HIV/HCV coinfection was reported in 9, 2 and 1 consultant(s) respectively. Based on the WHO classification, severe immunosuppression (CD4 count 3) was recorded in HIV and Plasmodium monoinfected individuals: 12.5% and 6.6% respectively. For HIV mono-infected consultants, 12.5% were highly immunocompromised and 43.75% had a CD4 count between 500 and 2000 cells/mm3. Severe immunosuppression was more marked in HIV/Plasmodium (22.2%). HIV and Plasmodium mono-infected patients had higher hyperparasitemia compared to non-infected and the same result was observed with HCV/Plasmodium co-infected patients (42.8%) and HCV/Plasmodium co-infected patients. Severe immunosuppression was recorded in both HIV and Plasmodium monoinfected individuals. This severe immunosuppression was more pronounced in HIV/Plasmodium and HIV/HCV/Plasmodium coinfected patients. HIV and Plasmodium mono-infected patients had more pronounced hypertransaminasemia in women than in men.
    VL  - 7
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Laboratory of Physiology and Animal Biology, Faculty of Science, University of Douala, Douala, Cameroon

  • Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

  • Department of Biological Sciences, Laboratory of Parasitology, Mycology and Virology, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

  • Laboratory of Physiology and Animal Biology, Faculty of Science, University of Douala, Douala, Cameroon

  • HIV Voluntary Testing Center (HIV / VTC), Laquintinie Hospital, Douala, Cameroon

  • Laboratory of Physiology and Animal Biology, Faculty of Science, University of Douala, Douala, Cameroon

  • Department of Biological Sciences, Laboratory of Parasitology, Mycology and Virology, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

  • Sections